|
|
|
Volumn 22, Issue 4, 2007, Pages 24-25
|
|
Understand the benefits and risks of intraperitoneal therapy for advanced ovarian cancer.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CARBOPLATIN;
CISPLATIN;
MELPHALAN;
PACLITAXEL;
ARTICLE;
FEMALE;
HUMAN;
INFUSION;
INSTRUMENTATION;
INTRAPERITONEAL DRUG ADMINISTRATION;
METHODOLOGY;
NURSING;
ONCOLOGY NURSING;
OVARY TUMOR;
PATHOLOGY;
PERITONEAL CAVITY;
RISK FACTOR;
ANTINEOPLASTIC AGENTS;
CARBOPLATIN;
CISPLATIN;
FEMALE;
HUMANS;
INFUSIONS, PARENTERAL;
INJECTIONS, INTRAPERITONEAL;
MELPHALAN;
ONCOLOGIC NURSING;
OVARIAN NEOPLASMS;
PACLITAXEL;
PERITONEAL CAVITY;
RISK FACTORS;
|
|
EID: 34250156682
PISSN: 19351623
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (1)
|
|
References (0)
|
